Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Jul
28
Today In Oncology
Dabrafenib Plus Trametinib Improves Progression-Free Survival in BRAF V600E-Positive Differentiated Thyroid Cancer
Relapsed or Refractory Multiple Myeloma: Early-Phase Trial Investigates Novel Bispecific Antibody
Emergency Department Cancer Diagnosis Associated With Higher Mortality Across 16 Cancer Types
Avatrombopag Manages Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancer
Proton Pump Inhibitor, Antibiotic Exposure Linked to Worse Durvalumab Outcomes in Unresectable Stage III NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo